Literature DB >> 26455353

Microglial activation and progressive brain changes in schizophrenia.

L E Laskaris1,2,3, M A Di Biase1,3, I Everall3,4, G Chana2,3, A Christopoulos5, E Skafidas2,4, V L Cropley1,3, C Pantelis1,3,4.   

Abstract

Schizophrenia is a debilitating disorder that typically begins in adolescence and is characterized by perceptual abnormalities, delusions, cognitive and behavioural disturbances and functional impairments. While current treatments can be effective, they are often insufficient to alleviate the full range of symptoms. Schizophrenia is associated with structural brain abnormalities including grey and white matter volume loss and impaired connectivity. Recent findings suggest these abnormalities follow a neuroprogressive course in the earliest stages of the illness, which may be associated with episodes of acute relapse. Neuroinflammation has been proposed as a potential mechanism underlying these brain changes, with evidence of increased density and activation of microglia, immune cells resident in the brain, at various stages of the illness. We review evidence for microglial dysfunction in schizophrenia from both neuroimaging and neuropathological data, with a specific focus on studies examining microglial activation in relation to the pathology of grey and white matter. The studies available indicate that the link between microglial dysfunction and brain change in schizophrenia remains an intriguing hypothesis worthy of further examination. Future studies in schizophrenia should: (i) use multimodal imaging to clarify this association by mapping brain changes longitudinally across illness stages in relation to microglial activation; (ii) clarify the nature of microglial dysfunction with markers specific to activation states and phenotypes; (iii) examine the role of microglia and neurons with reference to their overlapping roles in neuroinflammatory pathways; and (iv) examine the impact of novel immunomodulatory treatments on brain structure in schizophrenia.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2016        PMID: 26455353      PMCID: PMC4742288          DOI: 10.1111/bph.13364

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  155 in total

Review 1.  Neuroimaging and emerging psychotic disorders: the Melbourne ultra-high risk studies.

Authors:  C Pantelis; D Velakoulis; S J Wood; M Yücel; A R Yung; L J Phillips; D-Q Sun; P D McGorry
Journal:  Int Rev Psychiatry       Date:  2007-08

2.  Cortical thickness reduction in individuals at ultra-high-risk for psychosis.

Authors:  Wi Hoon Jung; June Sic Kim; Joon Hwan Jang; Jung-Seok Choi; Myung Hun Jung; Ji-Young Park; Ji Yeon Han; Chi-Hoon Choi; Do-Hyung Kang; Chun Kee Chung; Jun Soo Kwon
Journal:  Schizophr Bull       Date:  2009-12-21       Impact factor: 9.306

3.  Olanzapine ameliorates neuropathological changes and increases IGF-1 expression in frontal cortex of C57BL/6 mice exposed to cuprizone.

Authors:  Handi Zhang; Yanbo Zhang; Haiyun Xu; Lingyan Wang; Abulimiti Adilijiang; Junhui Wang; Kelly Hartle; Zhijun Zhang; Dai Zhang; Qingrong Tan; Jiming Kong; Qingjun Huang; Xin-Min Li
Journal:  Psychiatry Res       Date:  2014-02-22       Impact factor: 3.222

4.  Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies.

Authors:  Bayanne Olabi; Ian Ellison-Wright; Andrew M McIntosh; Stephen J Wood; Ed Bullmore; Stephen M Lawrie
Journal:  Biol Psychiatry       Date:  2011-03-31       Impact factor: 13.382

5.  Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia.

Authors:  S E Arnold; J Q Trojanowski; R E Gur; P Blackwell; L Y Han; C Choi
Journal:  Arch Gen Psychiatry       Date:  1998-03

6.  Microglial activation is not equivalent to neuroinflammation in alcohol-induced neurodegeneration: The importance of microglia phenotype.

Authors:  S Alex Marshall; Justin A McClain; Matthew L Kelso; Deann M Hopkins; James R Pauly; Kimberly Nixon
Journal:  Neurobiol Dis       Date:  2013-01-08       Impact factor: 5.996

Review 7.  What is microglia neurotoxicity (Not)?

Authors:  Knut Biber; Trevor Owens; Erik Boddeke
Journal:  Glia       Date:  2014-03-03       Impact factor: 7.452

8.  Role for microglia in sex differences after ischemic stroke: importance of M2.

Authors:  Sheetal Bodhankar; Andrew Lapato; Yingxin Chen; Arthur A Vandenbark; Julie A Saugstad; Halina Offner
Journal:  Metab Brain Dis       Date:  2015-08-06       Impact factor: 3.584

9.  Ultrastructural alterations of myelinated fibers and oligodendrocytes in the prefrontal cortex in schizophrenia: a postmortem morphometric study.

Authors:  Natalya A Uranova; Olga V Vikhreva; Valentina I Rachmanova; Diana D Orlovskaya
Journal:  Schizophr Res Treatment       Date:  2011-06-28

10.  The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

View more
  64 in total

1.  Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28.

Authors:  K Collste; P Plavén-Sigray; H Fatouros-Bergman; P Victorsson; M Schain; A Forsberg; N Amini; S Aeinehband; S Erhardt; C Halldin; L Flyckt; L Farde; S Cervenka
Journal:  Mol Psychiatry       Date:  2017-02-14       Impact factor: 15.992

Review 2.  Inefficient neural system stabilization: a theory of spontaneous resolutions and recurrent relapses in psychosis

Authors:  Lena Palaniyappan
Journal:  J Psychiatry Neurosci       Date:  2019-11-01       Impact factor: 6.186

3.  Microglia and schizophrenia: where next?

Authors:  T Notter; U Meyer
Journal:  Mol Psychiatry       Date:  2017-03-28       Impact factor: 15.992

Review 4.  Small cells with big implications: Microglia and sex differences in brain development, plasticity and behavioral health.

Authors:  Lars H Nelson; Angela I Saulsbery; Kathryn M Lenz
Journal:  Prog Neurobiol       Date:  2018-09-05       Impact factor: 11.685

5.  Exercise ameliorates deficits in neural microstructure in a Disc1 model of psychiatric illness.

Authors:  Brian R Barnett; Jacqueline M Anderson; Maribel Torres-Velázquez; Sue Y Yi; Paul A Rowley; John-Paul J Yu
Journal:  Magn Reson Imaging       Date:  2019-05-16       Impact factor: 2.546

Review 6.  Dysregulation of miRNA and its potential therapeutic application in schizophrenia.

Authors:  Ting Cao; Xue-Chu Zhen
Journal:  CNS Neurosci Ther       Date:  2018-03-12       Impact factor: 5.243

7.  TSPO expression and brain structure in the psychosis spectrum.

Authors:  Sina Hafizi; Elisa Guma; Alex Koppel; Tania Da Silva; Michael Kiang; Sylvain Houle; Alan A Wilson; Pablo M Rusjan; M Mallar Chakravarty; Romina Mizrahi
Journal:  Brain Behav Immun       Date:  2018-06-12       Impact factor: 7.217

8.  Schizophrenia among patients with systemic lupus erythematosus: population-based cross-sectional study.

Authors:  S Tiosano; A Farhi; A Watad; N Grysman; R Stryjer; H Amital; D Comaneshter; A D Cohen; D Amital
Journal:  Epidemiol Psychiatr Sci       Date:  2016-07-26       Impact factor: 6.892

9.  Elevated TREM2 mRNA expression in leukocytes in schizophrenia but not major depressive disorder.

Authors:  Yuta Yoshino; Kentaro Kawabe; Kiyohiro Yamazaki; Shinya Watanabe; Shusuke Numata; Yoko Mori; Taku Yoshida; Junichi Iga; Tetsuro Ohmori; Shu-Ichi Ueno
Journal:  J Neural Transm (Vienna)       Date:  2016-04-29       Impact factor: 3.575

10.  Large-Scale Evidence for an Association Between Peripheral Inflammation and White Matter Free Water in Schizophrenia and Healthy Individuals.

Authors:  Maria A Di Biase; Andrew Zalesky; Suheyla Cetin-Karayumak; Yogesh Rathi; Jinglei Lv; Danny Boerrigter; Hayley North; Paul Tooney; Christos Pantelis; Ofer Pasternak; Cynthia Shannon Weickert; Vanessa L Cropley
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.